Drugs / Intravenous immunoglobulin (IVIG)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03866577 | Dec 2018 → Jun 2021 | autoimmune thrombocytopenic purpura | Momenta Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05662228 | Jun 2023 → May 2026 | Down syndrome | University of Colorado, Denver | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00176865 Comparator | Aug 2002 → Aug 2012 | Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, X-linked lymphoproliferative syndrome | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 4 | NCT05494593 Background | Feb 2023 → Aug 2025 | mucopolysaccharidosis type 2 | Takeda | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous Immunoglobulin (IVIG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05494593 ↗ |
| Known as | IVIg | “Intravenous immunoglobulin (IVIg)” NCT03866577 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Intravenous immunoglobulin (IVIg)” NCT03866577 ↗ |
| Route | Intravenous | “500 mg/kg IV weekly beginning on Day +7 until Day +100” NCT00176865 ↗ |